Tyrosine kinase inhibitors (TKIs) against ALK, such as crizotinib, alectinib, and ceritinib, have recently been developed and shown to exert a potent antitumor activity in pts with ALK-rearranged NSCLC [3–9]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.